Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma

被引:3
作者
Suaiti, Lubna [1 ]
Sullivan, Travis B. [2 ]
Rieger-Christ, Kimberly M. [2 ]
Servais, Elliot L. [3 ]
Suzuki, Kei [4 ,6 ]
Burks, Eric J. [1 ,2 ,5 ]
机构
[1] Boston Univ, Boston Med Ctr, Dept Pathol & Lab Med, Sch Med, Boston, MA USA
[2] Lahey Hosp & Med Ctr, Dept Translat Res, Ian C Summerhayes Cell & Mol Biol Lab, Burlington, MA USA
[3] Lahey Hosp & Med Ctr, Dept Surg, Burlington, MA USA
[4] Boston Univ, Boston Med Ctr, Dept Surg, Sch Med, Boston, MA USA
[5] Boston Univ Mallory Pathol Associates, Dept Pathol & Labora tory Med, 670 Albany St,Suite 304, Boston, MA 02118 USA
[6] INOVA, Dept Surg, Div Thorac Surg, Falls Church, VA USA
关键词
Lymphovascular; AJCC; NCCN; Pathology; Adjuvant; LYMPHOVASCULAR INVASION; PROGNOSTIC IMPACT; VESSEL INVASION; MICROVASCULAR INVASION; LYMPHATIC INVASION; NUCLEAR-DIAMETER; PRIMARY TUMOR; BLOOD-VESSEL; CANCER; INDICATOR;
D O I
10.1016/j.cllc.2022.12.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
NCCN-guidelines list vascular invasion (VI) as a risk-factor warranting consideration of adjuvant therapy among stage IB NSCLC. Among resected stage IA2-IB LUAD (n =344) and LUSC (n =102), VI predicted worse 5-year RFS for LUAD (64% vs. 90%, P <0.001) but not LUSC (83% vs. 80%, P =0.852). Guidelines should be modified to specify VI as a risk-factor only for stage I adenocarcinoma. Background: Lymphovascular invasion (LVI) is an adverse prognostic feature in resected stage I non-small cell lung cancer (NSCLC); however, it is unclear if the prognostic significance applies to both lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). Materials and Methods: A retrospective review of H&E-stained slides from surgically resected AJCC 8th ed. stage IA2-IB LUAD (n = 344) and LUSC (n = 102) from two institutions was performed. LVI was defined as either lymphatic (LI) or vascular (VI) invasion. Outcomes were assessed by 5-year recurrence-free survival (RFS) estimates using the Kaplan-Meier method. Results: The cohorts of LUAD and LUSC showed no significant differences in 5-year RFS (81% each), stage, age, race, or surgical procedure. The presence of LVI, VI, and LI was predictive of 5-year RFS for LUAD (LVI + 71% vs. LVI -92%, P < 0.001; VI + 64% vs. VI -90%, P < 0.001; LI + 75% vs. LI -84%, P = 0.030) but not LUSC (LVI + 84% vs. LVI -79%, P = 0.740; VI + 83% vs. VI-80%, P = 0.852; LI + 84% vs. LI -81%, P = 0.757). Among LUAD with LVI, VI was a stronger predictor of 5-year RFS than the remaining subset of VI-LI + tumors (64% vs. 87%, P = 004). Subset analysis of LI among LUAD stratified by VI showed no significant prognostic advantage to adding LI for risk stratification (VI-LI + 87% vs. VI-LI -92%, P = 0.347 & VI + LI + 62% vs. VI + LI-66%, P = 0.422). VI was present in 36% of LUAD. Conclusion: Vascular invasion is a strong predictor of recurrence in stage IA2-IB LUAD but not in LUSC. Adjuvant therapy trials should be directed at this subgroup.
引用
收藏
页码:E126 / E133
页数:8
相关论文
共 41 条
  • [1] Amin MB., 2017, AJCC Cancer Staging Manual, V8th ed.
  • [2] Burks Eric J, 2021, Cancer Treat Res Commun, V29, P100486, DOI 10.1016/j.ctarc.2021.100486
  • [3] Centre international de recherche sur le cancer, 2017, WHO CLASSIFICATION T, V4th ed
  • [4] Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men
    Cerfolio, Robert James
    Bryant, Ayesha S.
    Scott, Ethan
    Sharma, Manisha
    Robert, Francisco
    Spencer, Sharon A.
    Garver, Robert I.
    [J]. CHEST, 2006, 130 (06) : 1796 - 1802
  • [5] Comprehensive molecular profiling of lung adenocarcinoma
    Collisson, Eric A.
    Campbell, Joshua D.
    Brooks, Angela N.
    Berger, Alice H.
    Lee, William
    Chmielecki, Juliann
    Beer, David G.
    Cope, Leslie
    Creighton, Chad J.
    Danilova, Ludmila
    Ding, Li
    Getz, Gad
    Hammerman, Peter S.
    Hayes, D. Neil
    Hernandez, Bryan
    Herman, James G.
    Heymach, John V.
    Jurisica, Igor
    Kucherlapati, Raju
    Kwiatkowski, David
    Ladanyi, Marc
    Robertson, Gordon
    Schultz, Nikolaus
    Shen, Ronglai
    Sinha, Rileen
    Sougnez, Carrie
    Tsao, Ming-Sound
    Travis, William D.
    Weinstein, John N.
    Wigle, Dennis A.
    Wilkerson, Matthew D.
    Chu, Andy
    Cherniack, Andrew D.
    Hadjipanayis, Angela
    Rosenberg, Mara
    Weisenberger, Daniel J.
    Laird, Peter W.
    Radenbaugh, Amie
    Ma, Singer
    Stuart, Joshua M.
    Byers, Lauren Averett
    Baylin, Stephen B.
    Govindan, Ramaswamy
    Meyerson, Matthew
    Rosenberg, Mara
    Gabriel, Stacey B.
    Cibulskis, Kristian
    Sougnez, Carrie
    Kim, Jaegil
    Stewart, Chip
    [J]. NATURE, 2014, 511 (7511) : 543 - 550
  • [6] Commission on Cancer: a Quality Progrom of the American College of Surgeons, OPTIMAL RESORUCES CA
  • [7] Fujii T, 2014, ANTICANCER RES, V34, P3147
  • [8] Fujii T, 2014, ANTICANCER RES, V34, P1255
  • [9] Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
    Gillette, Michael A.
    Satpathy, Shankha
    Cao, Song
    Dhanasekaran, Saravana M.
    Vasaikar, Suhas V.
    Krug, Karsten
    Petralia, Francesca
    Li, Yize
    Liang, Wen-Wei
    Reva, Boris
    Krek, Azra
    Ji, Jiayi
    Song, Xiaoyu
    Liu, Wenke
    Hong, Runyu
    Yao, Lijun
    Blumenberg, Lili
    Savage, Sara R.
    Wendl, Michael C.
    Wen, Bo
    Li, Kai
    Tang, Lauren C.
    MacMullan, Melanie A.
    Avanessian, Shayan C.
    Kane, M. Harry
    Newton, Chelsea J.
    Cornwell, MacIntosh
    Kothadia, Ramani B.
    Ma, Weiping
    Yoo, Seungyeul
    Mannan, Rahul
    Vats, Pankaj
    Kumar-Sinha, Chandan
    Kawaler, Emily A.
    Omelchenko, Tatiana
    Colaprico, Antonio
    Geffen, Yifat
    Maruvka, Yosef E.
    Leprevost, Felipe da Veiga
    Wiznerowicz, Maciej
    Gumus, Zeynep H.
    Veluswamy, Rajwanth R.
    Hostetter, Galen
    Heiman, David, I
    Wyczalkowski, Matthew A.
    Hiltke, Tara
    Mesri, Mehdi
    Kinsinger, Christopher R.
    Boja, Emily S.
    Omenn, Gilbert S.
    [J]. CELL, 2020, 182 (01) : 200 - +
  • [10] Comprehensive genomic characterization of squamous cell lung cancers
    Hammerman, Peter S.
    Lawrence, Michael S.
    Voet, Douglas
    Jing, Rui
    Cibulskis, Kristian
    Sivachenko, Andrey
    Stojanov, Petar
    McKenna, Aaron
    Lander, Eric S.
    Gabriel, Stacey
    Getz, Gad
    Sougnez, Carrie
    Imielinski, Marcin
    Helman, Elena
    Hernandez, Bryan
    Pho, Nam H.
    Meyerson, Matthew
    Chu, Andy
    Chun, Hye-Jung E.
    Mungall, Andrew J.
    Pleasance, Erin
    Robertson, A. Gordon
    Sipahimalani, Payal
    Stoll, Dominik
    Balasundaram, Miruna
    Birol, Inanc
    Butterfield, Yaron S. N.
    Chuah, Eric
    Coope, Robin J. N.
    Corbett, Richard
    Dhalla, Noreen
    Guin, Ranabir
    Hirst, Anhe Carrie
    Hirst, Martin
    Holt, Robert A.
    Lee, Darlene
    Li, Haiyan I.
    Mayo, Michael
    Moore, Richard A.
    Mungall, Karen
    Nip, Ka Ming
    Olshen, Adam
    Schein, Jacqueline E.
    Slobodan, Jared R.
    Tam, Angela
    Thiessen, Nina
    Varhol, Richard
    Zeng, Thomas
    Zhao, Yongjun
    Jones, Steven J. M.
    [J]. NATURE, 2012, 489 (7417) : 519 - 525